Plan-B legislation wins approval in New York

Share this article:

The New York Senate gave legislative approval for pharmacists to dispense Plan-B without a physician's visit or prescription, regardless of a patient's age.
Before the drug can be sold, however, Governor George Pataki must sign it into law. Should the governor veto the bill, the move could be subject to a legislative override attempt.
"We are pleased," with the approval of the New York legislation, said Carol Cox, a spokeswoman for Barr Laboratories, which makes Plan B. "But we still have to wait and see if Governor Pataki signs it."
Currently, seven other states -- Alaska, California, Hawaii, Maine, New Mexico, Washington and New Hampshire -- allow pharmacists to dispense emergency birth control without a prescription.
The FDA's reproductive health advisory committee recommended making Plan B available without a prescription for women over the age of 16 in January, but the agency has yet to issue an official ruling on the matter.
Over-the-counter sale of Plan B has become contentious issue in the confirmation process of President Bush's pick of Acting Commissioner Lester Crawford to head the FDA.
Two Democratic U.S. Senators – Patty Murray of Washington and Hillary Clinton of New York – blocked a full senate vote on Acting Commissioner Lester Crawford earlier this month after a Senate panel voted to send his nomination to the floor.
Barr company officials have said in the past that they would launch an aggressive state-by-state effort to allow easier access if their FDA application fails.

 

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.